FANJ
AIMT

Financial Architects (New Jersey)’s Aimmune Therapeutics AIMT Stock Holding History

Financial Architects (New Jersey)’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-200
Closed -$4K – 1236
2019
Q2 		$4K Buy
+200
New +$4.12K ﹤0.01% 1047

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Architects (New Jersey)'s AIMT Position: Q3 2019 in Review

Financial Architects (New Jersey) sold out of Aimmune Therapeutics (AIMT) in Q3 2019, closing a stake of 200 shares — an estimated $4K sold.

Financial Architects (New Jersey) first reported a position in AIMT in Q2 2019 and held it in 1 quarter. The position peaked at $4K in Q2 2019. 146 funds tracked by Wall St. Rank hold AIMT as of Q3 2019.

  • Financial Architects (New Jersey) reported no remaining Aimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 200 Aimmune Therapeutics shares in Q3 2019, an estimated $4K.
  • Financial Architects (New Jersey) first reported a position in Aimmune Therapeutics in Q2 2019 and held it in 1 quarter.
  • Financial Architects (New Jersey)'s Aimmune Therapeutics position peaked at $4K in Q2 2019.
  • 146 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2019.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2019, filed 6 Nov 2019.